問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間：2026-07-18

高小雯Kao, Hsiao-Wen
  • Principal Investigator
  • Clinical Trial Experience (year) -15 years -2 個月

  • hsiaowen@cgmh.org.tw

Recruiting Trial

34Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

高小雯

List

59Cases

2019-12-01 - 2025-06-16

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2020-07-20 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2020-08-01 - 2028-09-30

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2020-12-25 - 2026-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2018-06-26 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion

  • Condition/Disease

    Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)

  • Test Drug

    Venetoclax

Participate Sites
7Sites

Recruiting6Sites

2018-11-22 - 2021-10-26

Phase II

Completed
A Phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response

  • Condition/Disease

    CML Chronic Myelogenous Leukemia Leukemia, Myeloid Chronic Hematologic Diseases

  • Test Drug

    ABL001, GLIVEC (STI571), Tasigna (AMN107)

Participate Sites
3Sites

Recruiting3Sites

2022-07-01 - 2027-07-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting6Sites

Recruiting2Sites

2026-06-01 - 2032-11-30

Phase II/III

Active
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia

  • Test Drug

    Azacitidine Pivekimab sunirine (IMGN632) Venetoclax Venetoclax Venetoclax

Participate Sites
5Sites

Not yet recruiting5Sites

2023-03-01 - 2028-10-16

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting7Sites

2023-05-01 - 2034-07-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB